Pharmaceutical composition comprising cannabidiol and bacillus subtilus

Abstract

The present invention relates to a composition comprising cannabidiol and Bacillus subtilus. If both substances are used together, they have surprisingly synergistic effects and enhance one another. Cannabidiol has antibacterial properties which are more advantageously enhanced by Bacillus subtilus beyond the pure combination in various areas of application. The invention also relates to a correspondingly configured method for preparing the composition, to a food supplement and to a cosmetic product.

Description

[0001] PHARMACEUTICAL COMPOSITION COMprising CANNABIDIOL AND BACILLUS SUBTILIS

[0002] The present invention relates to a composition comprising cannabidiol and Bacillus subtilis. When used together, both substances surprisingly exhibit synergistic effects and reinforce each other. Cannabidiol has antibacterial properties, which are further enhanced with Bacillus subtilis in various applications beyond the pure combination. Furthermore, the invention relates to a correspondingly configured process for producing the composition, as well as to a dietary supplement and a cosmetic product.

[0003] According to the current state of the art, the effects of cannabidiol (CBD) can be improved by various methods, such as increasing the dosage. Increasing the dose can enhance the effects of cannabidiol. It is recommended to start with a low dose and gradually increase to avoid unwanted side effects. Using full-spectrum cannabidiol products also increases the effects of cannabidiol. In addition to cannabidiol, full-spectrum cannabidiol products also contain other cannabinoids, terpenes, and flavonoids, which, when combined with cannabidiol, act synergistically and can enhance the effects of CBD. Liposomal cannabidiol products can also be used. Liposomal cannabidiol products are coated with phospholipids and, due to their smaller size and higher bioavailability, can enhance the effects of cannabidiol.Using cannabidiol products in combination with other natural substances also increases the effect. Cannabidiol can be enhanced when combined with other natural substances such as turmeric, ginger, or pepper, as these substances can improve the bioavailability of cannabidiol and enhance its effects.

[0004] There is a need in the state of the art to create alternative compositions or processes for their production that can be produced with minimal technical effort. Increasing the dose of cannabidiol should be avoided for cost-effectiveness reasons. Cannabidiol is technically complex to produce and should be administered in the smallest possible doses without weakening its effects.

[0005] The aim is therefore to create an alternative method or composition that increases the efficacy of cannabidiol. This increase in efficacy should be achieved in a technically efficient manner, avoiding the need to simply administer a larger amount of the complexly produced cannabidiol. Furthermore, a corresponding dietary supplement and a cosmetic product should be proposed.

[0006] The object is achieved by a composition having the features according to claim 1. Further advantageous embodiments are specified in the subclaims.

[0007] Accordingly, a pharmaceutical composition is proposed comprising Bacillus subtilis and cannabidiol.

[0008] CBD (cannabidiol) and Bacillus subtilis are two separate substances that have previously been used separately. Cannabidiol is a compound extracted from the hemp plant and is available in various forms, including capsules and topicals. Bacillus subtilis is a type of bacterium found in the environment and used in the food industry and agriculture.

[0009] There is no direct combination of cannabidiol and Bacillus subtilis in the prior art, as they are different substances used in different applications. This is proposed by the invention because, in some cases, they can be used together to achieve synergistic benefits.

[0010] In addition, the invention overcomes the disadvantage that in the prior art, silicon must be added to the Bacillus subtilis.

[0011] Surprisingly, the invention discovered that this is unnecessary, thus saving silicon. Some of the potential benefits of cannabidiol include reducing pain and inflammation, improving sleep and mood, and supporting the immune system. Bacillus subtilis, on the other hand, can help support the digestive system by clearing the intestinal tract of harmful bacteria and promoting the growth of healthy bacteria.

[0012] When used together, both substances surprisingly have synergistic effects, reinforcing each other. For example, Bacillus subtilis can improve the body's absorption of CBD and support immune system strengthening, while CBD helps reduce inflammation in the gut and soothe the digestive system, among other things. For example, Bacillus subtilis combats bacteria that are harmful to the intestinal flora or food digestion by destroying their cell walls. It also contributes to the good absorption of nutrients into the blood. This is particularly beneficial for cannabidiol.

[0013] The proposed composition can be used to treat digestive disorders or support intestinal health in a mammal, preferably in humans, through the administration of a pharmaceutical composition containing an effective amount of cannabidiol (CBD) and Bacillus subtilis. The combination of cannabidiol and Bacillus subtilis exhibits synergistic effects to promote the growth of beneficial intestinal bacteria, inhibit the growth of harmful bacteria, reduce inflammation and damage in the intestine, and strengthen the immune system. Furthermore, the effects of cannabidiol are maintained by Bacillus subtilis, and cannabidiol is absorbed in particularly large quantities.

[0014] Cannabidiol is complex to produce, making Bacillus subtilis particularly suitable for improving cannabidiol absorption. This has the technical effect that cannabidiol only needs to be ingested in smaller doses, as it is absorbed in higher concentrations. Surprisingly, Bacillus subtilis is particularly suitable for the use of cannabidiol because it is completely harmless. Unlike other state-of-the-art bacteria, Bacillus subtilis does not cause disease but can even help fight bacterial infections. However, not all strains of Bacillus subtilis can synthesize antibiotics.

[0015] In this case, a pharmaceutical composition is proposed, whereby "pharmaceutical" is understood to be optional. Surprisingly, it was also recognized that cannabidiol does not have to be used as an oil.

[0016] Bacillus subtilis is a bacterium that occurs naturally in the digestive tract of animals and humans. It is also known as a probiotic organism, meaning it can have a positive effect on digestive tract health. Some of the possible synergistic effects of Bacillus subtilis in combination with cannabidiol include:

[0017] - Digestive support: Bacillus subtilis can help restore intestinal flora balance and improve digestion. It can also help reduce food allergies and intolerances.

[0018] - Immune system support: Bacillus subtilis can strengthen the immune system in combination with cannabidiol by promoting the production of immune cells and antibodies that fight infections.

[0019] - Protection against harmful bacteria: Bacillus subtilis can help inhibit harmful bacteria in the digestive tract and promote the growth of beneficial bacteria, improving digestive tract health.

[0020] - Support for weight loss: Cannabidiol is said to have appetite-suppressing properties. Bacillus subtilis can help improve metabolism and support the body in burning fat, which can lead to weight loss. Surprisingly, the invention has discovered that both substances enhance each other's effects even further than when used together.

[0021] - Support in combating diarrhea: Bacillus subtilis can help combat diarrhea by inhibiting the growth of harmful bacteria in the digestive tract and restoring intestinal flora, which cannabidiol supports.

[0022] According to one aspect of the present invention, the composition comprises carrier materials and / or fillers. This has the advantage that administration can take place in a suitable volume and the composition can be combined with other substances.

[0023] According to a further aspect of the present invention, cannabidiol makes up at least 60% of the composition. This has the advantage that a predominant proportion of cannabidiol, preferably 80 or 90%, can be used. Bacillus subtilis is administered in relatively small amounts.

[0024] According to a further aspect of the present invention, the cannabidiol constitutes 12, 25, 30 or 50% of the composition.

[0025] According to a further aspect of the present invention, the composition comprises fiber, vitamins, and / or other probiotics. This has the advantage of allowing additional effects to be achieved, and in particular, the use of additional probiotics ensures the effectiveness of Bacillus subtilis. In this way, the effectiveness of cannabidiol is further enhanced, as it is better absorbed by the human body.

[0026] According to a further aspect of the present invention, the pharmaceutical composition has a higher concentration of cannabidiol than of Bacillus subtilis. This has the advantage of creating a favorable mixing ratio and primarily administering the cannabidiol, with the Bacillus subtilis being used only in a supporting capacity.

[0027] According to a further aspect of the present invention, the Bacillus subtilis is selected from one of the strains LA13030, CU1, HU58, DSM 33619, DE 111, DSM 15544, Rosell-179, and / or PXN 21. This has the advantage of selecting Bacillus subtilis strains that enable improved intestinal colonization and viability in the gastrointestinal tract. These have proven particularly effective in combination with cannabidiol.

[0028] According to a further aspect of the present invention, the composition comprises food additives. This has the advantage that the administration can be varied for the end user and can be presented in a suitable and appealing manner.

[0029] The object is also achieved by a method for producing a pharmaceutical composition, comprising providing Bacillus subtilis; providing cannabidiol; and mixing the Bacillus subtilis and cannabidiol.

[0030] The problem is also solved by a dietary supplement and a cosmetic product.

[0031] Further advantages, features, and details of the invention will become apparent from the following description, in which aspects of the invention are described in detail with reference to the drawings. The features mentioned in the claims and in the description may each be essential to the invention individually or in any combination. Likewise, the features mentioned above and those further described here may be used individually or in any combination. The figure shows:

[0032] Figure 1: a schematic flow diagram of the proposed method according to one aspect of the present invention.

[0033] Figure 1 shows a schematic flow diagram of a method for producing a pharmaceutical composition, comprising providing 100 Bacillus subtilis; providing 101 cannabidiol; and mixing 102 the Bacillus subtilis and cannabidiol.

Claims

Patent claims 1. Pharmaceutical composition comprising: - Bacillus subtilis; and - Cannabidiol.

2. Pharmaceutical composition according to claim 1, characterized in that the composition comprises carrier materials and / or fillers.

3. Pharmaceutical composition according to claim 1 or 2, characterized in that the cannabidiol constitutes at least 60% of the composition.

4. Pharmaceutical composition according to one of the preceding claims, characterized in that the composition comprises fiber, vitamins and / or other probiotics.

5. Pharmaceutical composition according to one of the preceding claims, characterized in that the pharmaceutical composition has a higher concentration of cannabidiol than of Bacillus subtilis.

6. Pharmaceutical composition according to one of the preceding claims, characterized in that the Bacillus subtilis is selected from one of the strains LA13030, CU1, HU58, DSM 33619, DE 111, DSM 15544, Rosell-179 and / or PXN 21.

7. Pharmaceutical composition according to one of the preceding claims, characterized in that the composition comprises food additives.

8. A process for the preparation of a pharmaceutical composition comprising: Providing (100) Bacillus Subtilis; - Providing (101 ) cannabidiol; and - Mixing (102) of Bacillus subtilis and cannabidiol.

9. A food supplement comprising a pharmaceutical composition according to any one of claims 1 to 7.

10. A food supplement according to claim 12, characterized in that it is in the form of an oil, oily solution, tea, granules, tablet, capsule, lozenge, chewing gum and / or candy.

11. A cosmetic product comprising a pharmaceutical composition according to any one of claims 1 to 7.

12. A cosmetic product according to claim 11, characterized in that it is in the form of a cream.

Images